BioInvent International
40,7 SEK -5,57%2 investorer følger denne virksomhed
BioInvent International is active in the pharmaceutical industry. The company focuses on the research and development of antibody drugs used in the treatment of cancer. The company has its own development platform and collaborations take place via the company's partners. In the early development phase, the company is working to recreate the disease biology to get indications about the substance's effect on the disease. The head office is located in Lund, Sweden.
Omsætning
-
EBIT %
-
P/E
-
Udbytteafkast, %
-
Kursmål
-
Anbefaling
-
Opdateret
-
NASDAQ Stockholm
BINV
Daglig lav / høj pris
40,6 / 43,9
SEK
Markedsværdi
2,68 mia. SEK
Aktieomsætning
3,6 mio. SEK
Volumen
87 t
Seneste videoer
Finanskalender
Delårsrapport
31.10.2024
Større aktionærerKilde: Millistream Market Data AB
| Ejer | Kapital | Stemmer |
|---|---|---|
| Redmile Group, LLC | 15,2 % | 15,2 % |
| Van Herk Investments | 10,1 % | 10,1 % |
| Forbion | 9,8 % | 9,8 % |
| HBM Healthcare Investments Ltd | 7,7 % | 7,7 % |
| Omega Fund IV, LP | 6,3 % | 6,3 % |
| Fjärde AP-fonden | 6,1 % | 6,1 % |
| Goldman Sachs International, W8IMY | 3,4 % | 3,4 % |
| Avanza Pension Försäkring | 3,1 % | 3,1 % |
ViserAlle indholdstyper
BioInvent and Transgene’s Oncolytic Virus BT-001 Shows Promising Antitumor Activity in Ongoing Phase 1/2a Trial in Solid Tumors that Failed Previous Treatments
BioInvent International AB: BioStock: BioInvent makes a strong entrance at ESMO in Barcelona
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools